NCI GCSC Endometrial Cancer Clinical Trials Planning Meeting (Overview)


Welcome to the registration site of the NCI's Gynecologic Cancer Steering Committee Clinical Trials Planning Meeting on 'Refining the Approach to Endometrial Cancer in the Immunotherapy Era'.

The utilization of immune checkpoint inhibitor (ICI) therapy in epithelial endometrial cancer has become the current treatment paradigm. Its widespread use in second line treatment and anticipated move into the front line space for some endometrial cancer subtypes leaves a critical unmet need to better understand the best time in the disease life cycle into which ICI therapy can be administered, for which group of patients it should be used, and how to optimize its use.

The goal of this Clinical Trials Planning Meeting is to develop clinical trials that optimize therapy under the ICI treatment paradigms. To achieve this goal, the meeting will bring together experts from across the endometrial cancer research community and key stakeholders to develop collaborative interdisciplinary approaches to address key questions and propose next generation clinical trial concepts in this disease space.

Meeting Date/Time:

Monday, January 08, 2024; 10:00 a.m. - 6:00 p.m. Eastern Time [Open Session ends 5 pm]
Tuesday, January 09, 2024; 10:00 a.m. - 12:30 p.m. Eastern Time [Closed Session]
Tuesday, January 09, 2024; 12:30 p.m. - 1:30 p.m. Eastern Time [Executive Session; Closed]


Virtual event; meeting access information will be sent via email/Outlook calendar invitation.

Registration deadline:

Please register for this meeting by January 02, 2024

For questions related to the meeting, please contact: Dr. Wolf Lindwasser or Ramy Serour.